Ortoma AB Series B (ORT-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ortoma AB Series B (ORT-B) has a cash flow conversion efficiency ratio of -0.120x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-17.13 Million ≈ $-1.84 Million USD) by net assets (Skr142.72 Million ≈ $15.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ortoma AB Series B net asset quality index to measure how much of total assets are equity-financed.
Ortoma AB Series B - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Ortoma AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Ortoma AB Series B to evaluate the quality of earnings relative to operating cash generation.
Ortoma AB Series B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ortoma AB Series B ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GenMont Biotech Inc
TW:3164
|
0.011x |
|
Advance Synergy Bhd
KLSE:1481
|
0.065x |
|
Tolins Tyres Ltd
NSE:TOLINS
|
N/A |
|
Done.ai Group AB
ST:TINGS-B
|
0.009x |
|
International Meal Company Alimentação S.A
SA:MEAL3
|
0.004x |
|
Kinatico Ltd
AU:KYP
|
0.084x |
|
Dreamus Company
KQ:060570
|
0.097x |
|
Molinos Juan Semino SA
BA:SEMI
|
0.001x |
Annual Cash Flow Conversion Efficiency for Ortoma AB Series B (2021–2025)
The table below shows the annual cash flow conversion efficiency of Ortoma AB Series B from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see ORT-B company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr142.72 Million ≈ $15.36 Million |
Skr6.04 Million ≈ $649.78K |
0.042x | +131.12% |
| 2024-12-31 | Skr161.91 Million ≈ $17.42 Million |
Skr-22.01 Million ≈ $-2.37 Million |
-0.136x | -276.65% |
| 2023-12-31 | Skr173.54 Million ≈ $18.68 Million |
Skr13.35 Million ≈ $1.44 Million |
0.077x | +206.13% |
| 2022-12-31 | Skr114.29 Million ≈ $12.30 Million |
Skr-8.29 Million ≈ $-891.82K |
-0.073x | +37.94% |
| 2021-12-31 | Skr130.04 Million ≈ $13.99 Million |
Skr-15.19 Million ≈ $-1.63 Million |
-0.117x | -- |
About Ortoma AB Series B
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and … Read more